BB Biotech’s Moderna MRNA Stock Holding History

BB Biotech’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$97.4M	Hold	4,785,681	–	–	2.45%	14
2018 Q4	$73.1M	Buy	+4,785,681	New	+$78.6M	2.34%	15

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

BB Biotech's MRNA Position: Q1 2019 in Review

BB Biotech held its Moderna (MRNA) position steady in Q1 2019 at 4,785,681 shares worth $97.4M. The position accounts for 2.45% of the portfolio, ranked #14.

BB Biotech first reported a position in MRNA in Q4 2018 and has held it in 2 quarters since. 106 funds tracked by Wall St. Rank hold MRNA as of Q1 2019.

BB Biotech held 4,785,681 shares of Moderna worth $97.4M as of Q1 2019.
BB Biotech left its Moderna share count unchanged in Q1 2019.
Moderna made up 2.45% of BB Biotech's portfolio in Q1 2019, its #14 holding.
BB Biotech first reported a position in Moderna in Q4 2018 and has held it in 2 quarters since.
106 funds tracked by Wall St. Rank held Moderna as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.